Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- Check6 days agoChange DetectedThe page no longer displays a 403 error and instead shows the ClinicalTrials.gov site shell, with an updated revision label. The study record content is not visible.SummaryDifference0.8%

- Check13 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now displays a 403 Forbidden error page, blocking access to the study record content. The additions include the 403 message and standard site header/footer, indicating restricted access to the content.SummaryDifference20%

- Check55 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, indicating a minor page version update rather than substantive content changes.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page revision tag was updated from v3.6.4 to v3.6.5, signaling a new build of the study page. No changes to the study details or displayed information are evident.SummaryDifference0.0%

- Check90 days agoChange DetectedThe page shows an updated revision tag to Revision: v3.6.4, reflecting an internal update to the study record. There is no indication of changes to trial content or data in this update.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.